Positive Findings In Pelvic MRIs In Relapsed Prostate Cancer After Failed Radical Prostatectomy

There has been a lot of conversation about the role of and the use of multi-parametric MRIs in the initial diagnostic stages of prostate cancer, but little is known about its potential clinical application in the use of early salvage radiotherapy after failed radical prostatectomy. In a study to exam the potential of multi-parametric MRIs [...]

Startling Fact: PSA Testing Frequency Changes PSA Doubling Time – A Time Honored Surrogate Biomarker is Not Valid!

In our quest to understand our prostate cancer we have developed many “measures” of our disease aggressiveness and progression.  Many of these measures are generally accepted has valid, but many have never been validated. One example is the prognostic nature of PSA Doubling Time (PSADT) in men with biochemically recurrent prostate cancer (BRPC or PSA [...]

Salvage Radio Therapy Extends Life Without Regard to PSA Doubling Time

Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA doubling time (DT,< 6 months). They then asked whether such a benefit also exits in men with a protracted PSA [...]

Impact of Postoperative PSA Scores on Recurrence and the use of Salvage Therapy on the Risk of Death

In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]

Changes of PSA Doubling Time is Associated with Disease Progression in Men with Biochemically Relapsed Prostate Cancer Treated with Intermittent Androgen Deprivation

Researchers at the The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland studied the relationship between the change of PSA doubling time (PSADT) and disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. They retrospectively analyzed the data from 96 men diagnosed with biochemically relapsed prostate cancer (BRPC) who [...]

Go to Top